Thornton & Ross News

Thornton & Ross triumphant in industry awards

Huddersfield, October 4, 2019 – Huddersfield-based pharmaceutical company Thornton & Ross has received national recognition for six of its products at the national 2019 ‘Most Valuable Product’ (MVP) Awards in pharmacy.

The firm’s Nizoral® Anti-Dandruff Shampoo was voted winner in the Hair and Scalp Care category, while five other products were highly commended in their categories:

Child Health Care® Virasoothe
Cold & Cough Covonia® Chesty Cough Mixture
Cold & Cough Covonia Dry & Tickly Cough
Infant Gastrointestinal Care Co Lactase Drops
Sexual Health KY Jelly®

The awards are split into 28 categories covering a range of common conditions and health-related issues that consumers rely on pharmacy help and advice with.

The shortlist was chosen by an 18-strong expert panel including retail buyers and community pharmacists from across the UK from pharmacy brands including Boots, Tesco and Lloyds Pharmacy. Voting on all shortlisted products was opened out to all pharmacy staff in the UK, with thousands casting their votes.

Thornton & Ross now has the chance to secure the Overall MVP Award, which will be chosen by industry professionals attending The Pharmacy Show in October.

The overall winner will be revealed at The MVP 2019 Celebratory Lunch on 1 November in London. A cross functional team of 10 will be attending from Thornton & Ross.

Speaking about the awards success, head and executive vice-president of Thornton & Ross Roger Scarlett-Smith said: “We are thrilled with Thornton & Ross’s success at the MVP awards, particularly as this is the first year that we have submitted entries. To be recognized across six different categories, with a clear win for Nizoral, is a fantastic achievement and underlines our commitment to delivering the best quality products to our customers.”

Thornton & Ross develops, manufactures and supplies a wide range of branded over-the-counter medicines, dermatological solutions and other healthcare and hygiene products including Zoflora®, Hedrin® and Setlers®. It is part of the German-based STADA Group.

The business recently announced a recruitment drive to fill 40 positions it has created at its Linthwaite production site as it continues to expand.

Scarlett-Smith adds: “We have ambitious plans to strengthen our foothold across the UK pharmaceutical industry and in the first half of this year, we gained broad based growth across the range, from our Natures Aid® natural supplements, to Zoflora® in home hygiene, and to our prescription therapies for dermatology and myeloma. We recently closed our deal with GSK to acquire some well-known brands including Oilatum® and Savlon® skin care brands. These sales will add to growth in the second half of 2019.”

MVP Team 2019 Clockwise From bottom-left: Kelly Auty (Covonia), Anna Flowers (sales), Hannah Rice (sales), Jack Dearden (Care), Phoebe Buckley (KY Jelly and Nizoral), Amy Barker (Metanium and Tixylix)


STADA to Become a Major Pharma Player in Ukraine by Acquiring Biopharma's Pharmaceutical Prescription and Consumer Health Business

The STADA Group continues its growth trajectory in Europe. The company, announced that it is acquiring the pharmaceutical business of Biopharma, one of the key pharmaceutical producers in Ukraine.

Click for more info

Is veganism good for your health?

The Future of Your Health report indicates that nearly a third of Brits don’t think so

Click for more info


Biopharmaceutical company Alvotech and global pharmaceutical company STADA Arzneimittel AG ("STADA") today announced that they have entered into an exclusive strategic partnership for the commercialisation of seven biosimilars in all key European markets and selected markets outside Europe.

Click for more info

STADA invests $660 Million USD in Takeda's OTC portfolio in Russia/CIS to become a major player in these branded markets

STADA to acquire a portfolio of approximately 20 selected OTC and prescription pharmaceutical products in Russia, Georgia and CIS countries

Click for more info

STADA to acquire Walmark - a leading Consumer Healthcare company in Central Europe

STADA Arzneimittel AG ('STADA' or 'the Group') today announces the acquisition of Walmark a.s. ('Walmark' or 'the company') from Mid Europa Partners for an undisclosed consideration.

Click for more info

Q&A 2019 Pharmacy Show

A Q&A Session with Phoebe Buckley on the 2019 Pharmacy Show

Click for more info

STADA Health Report 2019

More than half of people in UK are optimistic about the future of health

Click for more info

Leading pharmaceutical company invests in seven-figure state-of-the-art facility

Huddersfield pharmaceutical company Thornton & Ross is expanding, with a new seven-figure state-of-the-art facility due to open at the beginning of January.

Click for more info

>> News Archive